Curriculum Vitaes

Kyoko INAGAKI-OHARA

  (稲垣 匡子)

Profile Information

Affiliation
Guest Professor, Fujita Health University
Degree
Immunology(Nagoya University)

Other name(s) (e.g. nickname)
Kyoko INAGAKI-OHARA
J-GLOBAL ID
200901086797054062
researchmap Member ID
5000058550

Research Areas

 1

Papers

 34
  • Yuta Kinoshita, Seiya Arita, Takumi Ogawa, Ayane Takenouchi, Kyoko Inagaki-Ohara
    Archives of biochemistry and biophysics, 729 109379-109379, Oct 30, 2022  
    Obesity is a risk factor for gastrointestinal malignancies and tumors. However, which factors either protect or predispose the gastrointestinal organs to high-fat diet (HFD)-induced neoplasia remains unclear. Here, we demonstrate that HFD impacts the stomach to a greater extent as compared to the colorectum, resulting in leptin receptor (LepR) signaling-mediated neoplasia in the tissues. HFD activated leptin signaling, which in turn, accelerates the pathogenesis in the gastric mucosa more than that in the colorectum along with ectopic TFF3 expression. Moreover, in the stomach, higher levels of phosphorylated epidermal growth factor receptor (EGFR) in addition to the activation of STAT3 and Akt were observed as compared to the colorectum. The mice with LepR deletion in the gastrointestinal epithelium exhibited a suppressed induction of leptin, TFF3, and phosphorylated EGFR in the stomach, whereas the levels in the colorectum were insignificant. In co-transfected COS-7 cells with LepR and EGFR plasmid DNA, leptin transactivated EGFR to accelerate TFF3 induction along with activation of STAT3, ERK1/2, Akt, and PI3K p85/p55. Furthermore, TFF3 could bind to EGFR but did not transactivate LepR. Leptin-induced TFF3 induction was markedly suppressed by inhibitors of PI3K (LY294002) and EGFR (Erlotinib). Together, these results suggest a novel role of LepR-mediated signaling in transactivating EGFR that leads to TFF3 expression via the PI3K-Akt pathway. Therefore, this study sheds light on the identification of potentially new therapeutic targets for the treatment of pre-cancerous symptoms in stomach and colorectum.
  • Arita S, Ogawa T, Murakami Y, Kinoshita Y, Okazaki M, Inagaki-Ohara K
    Nutrients, 11(9), Sep, 2019  Peer-reviewed
    Excess of fat intake leads to obesity and causes a variety of metabolic diseases and cancer. We previously demonstrated that high-lard diet induces intestinal metaplasia, a precancerous lesion of the stomach mediated by leptin signaling. This study aims to investigate which kinds of dietary fat cause the intestinal metaplasia onset. We fed eight kinds of high-fat diets (HFDs) of animal or plant origin to mice evaluated their effect on gastric pathogenesis. Five types of dietary fat were divided according to their observed effects: Obese with high metaplasia (group I; beef tallow, lard, and hydrogenated coconut oil), non-obese with high metaplasia (group II; linseed oil), obese without metaplasia (group III; corn oil and olive oil), non-obese without metaplasia (group IV, soybean oil) and lean without metaplasia (group V; cocoa butter). The group I and II diets induced leptin, phosphorylated leptin receptor (ObR), signal transducer and activator 3 (STAT3), and increased intracellular β-catenin accumulation in the stomach. Moreover, mice fed these HFDs with 1-methyl-3-nitro-1-nitrosoguanidine (MNNG), a gastric carcinogen, and further accelerated dysplasia in the stomach. Lactobacillus occupancy in the stomach increased in all HFDs except hydrogenated coconut oil. Our findings suggest that HFDs inducing leptin signaling accelerate the enhancement of protumorigenic gastric microenvironment independent of body mass gain or microbiome changes.
  • Arita S, Inagaki-Ohara K
    Nutrition (Burbank, Los Angeles County, Calif.), 67-68 110556-110556, Jul, 2019  Peer-reviewed
    OBJECTIVES: Obesity is a risk factor for malignancy in various tissues, and has been associated with gut microbiota alterations. However, the link between obesity-associated microbiota and gastric pathogenesis has not been clarified. We demonstrated that high-fat-diet (HFD) feeding causes intestinal metaplasia, which are precancerous lesions of the stomach, with augmented gastric leptin signaling. The aim of this study was to investigate the precise role of leptin signaling in the altered microbiota composition and pathogenesis in the stomach during diet-induced obesity. METHODS: Male C57 BL/6 J, leptin receptor (Lepr)-mutated db/db, and gastrointestinal epithelium-specific Lepr conditional knockout (T3 b-Lepr cKO) mice were fed a HFD or control diet. Gastrointestinal microbiota was analyzed by 16 S rRNA gene sequences and quantitative polymerase chain reaction. Transplantation of gastric microbiota of HFD-fed mice was performed to evaluate metaplasia onset in recipient mice. RESULTS: One week of HFD caused severe microbial dysbiosis in the stomach. The microbiota changes were accompanied by increased gastric leptin, leading to the consequent development of intestinal metaplasia. Transplantation of gastric microbiota from HFD-fed mice induced intestinal metaplasia in recipient mice; however, only a limited effect on pathogenesis was noted. HFD-fed db/db mice did not show a decrease in microbial abundance. Moreover, T3 b-Lepr cKO mice failed spontaneous obesity, and suppressed decreased abundance of gastric microbiota and occurrence of intestinal metaplasia during HFD feeding similar to db/db mice. CONCLUSIONS: Gastric leptin signaling modulates the gastric microbiota community and regulates the pathogenesis in the gastric mucosa.
  • Inagaki-Ohara K
    International journal of molecular sciences, 20(11), May, 2019  Peer-reviewed
    Leptin, an adipocyte-derived hormone and its receptor (ObR) expressed in the hypothalamus are well known as an essential regulator of appetite and energy expenditure. Obesity induces abundant leptin production, however, reduced sensitivity to leptin leads to the development of metabolic disorders, so called leptin resistance. The stomach has been identified as an organ that simultaneously expresses leptin and ObR. Accumulating evidence has shown gastric leptin to perform diverse functions, such as those in nutrient absorption and carcinogenesis in the gastrointestinal system, independent of its well-known role in appetite regulation and obesity. Overexpression of leptin and phosphorylated ObR is implicated in gastric cancer in humans and in murine model, and diet-induced obesity causes precancerous lesions in the stomach in mice. While the underlying pathomechanisms remain unclear, leptin signaling can affect gastric mucosal milieu. In this review, we focus on the significant role of the gastric leptin signaling in neoplasia and tumorigenesis in stomach in the context of hereditary and diet-induced obesity.
  • Kinoshita Y, Arita S, Murazoe H, Kitamura K, Ashizuka S, Inagaki-Ohara K
    Human cell, 32(1) 12-21, Oct, 2018  Peer-reviewed
    Adrenomedullin (AM) exerts a potent anti-inflammatory effect. Intrarectal or consecutive intravenous administrations of AM reduce pathological manifestations in rodent colitis models. However, in clinical applications, a safer administration route that provides stronger alleviation of patient burden is preferred. We investigated whether subcutaneously administered AM is effective against dextran sulfate sodium (DSS)-induced colitis. C57BL/6J mice were administered 1% DSS in drinking water and received AM at 8, 40 or 80 nmol/kg subcutaneously once a day for 7 consecutive days. Subcutaneously administered AM significantly and dose-dependently ameliorated body weight loss, diarrhea, and histological severity of colonic inflammation in DSS-treated mice. The AM therapeutic effect was associated with the upregulation of the production of autocrine AM, and expression of cAMP, c-fos, KLF4, and downregulation of STAT3 and NF-κB p65 phosphorylation, as well as a decrease in proinflammatory cytokine expression in the colon. Subcutaneous AM treatment potently attenuated DSS-induced colitis, which suggests that AM administered subcutaneously in ulcerative colitis (UC) patients may decrease diseases burden and improve quality of life.
  • Nishino, Tasuku, Matsunaga, Ryota, Jikihara, Hiroshi, Uchida, Moe, Maeda, Akane, Qi, Guangying, Abe, Takaya, Kiyonari, Hiroshi, Tashiro, Satoshi, Inagaki-Ohara, Kyoko, Shimamoto, Fumio, Konishi, Hiroaki
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1861(11) 1816-1827, Nov, 2016  Peer-reviewed
    Cardiolipin and phosphatidic acid-binding protein (CLPABP) is a pleckstrin homology domain-containing protein and is localized on the surface of mitochondria of cultured cells as a large protein-RNA complex. To analyze the physiological functions of CLPABP, we established and characterized a CLPABP knockout (KO) mouse. Although expression levels of CLPABP transcripts in the developmental organs were high, CLPABP KO mice were normal at birth and grew normally when young. However, old male mice presented a fatty phenotype, similar to that seen in metabolic syndrome, in parallel with elevated male- and age-dependent CLPABP gene expression. One of the reasons for this obesity in CLPABP KO mice is dependence on increases in leptin concentration in plasma. The leptin transcripts were also upregulated in the adipose tissue of KO mice compared with wild-type (WT) mice. To understand the difference in levels of the transcriptional product, we focused on the effect of CLPABP on the stability of mRNA involving an AU-rich element (ARE) in its 3'UTR dependence on the RNA stabilizer, human antigen R (HuR), which is one of the CLPABP-binding proteins. Increase in stability of ARE-containing mRNAs
  • Nishino T, Matsunaga R, Jikihara H, Uchida M, Maeda A, Qi G, Abe T, Kiyonari H, Tashiro S, Inagaki-Ohara K, Shimamoto F, Konishi H
    Biochimica et biophysica acta, 1861(11) 1816-1827, Nov, 2016  Peer-reviewed
    Cardiolipin and phosphatidic acid-binding protein (CLPABP) is a pleckstrin homology domain-containing protein and is localized on the surface of mitochondria of cultured cells as a large protein-RNA complex. To analyze the physiological functions of CLPABP, we established and characterized a CLPABP knockout (KO) mouse. Although expression levels of CLPABP transcripts in the developmental organs were high, CLPABP KO mice were normal at birth and grew normally when young. However, old male mice presented a fatty phenotype, similar to that seen in metabolic syndrome, in parallel with elevated male- and age-dependent CLPABP gene expression. One of the reasons for this obesity in CLPABP KO mice is dependence on increases in leptin concentration in plasma. The leptin transcripts were also upregulated in the adipose tissue of KO mice compared with wild-type (WT) mice. To understand the difference in levels of the transcriptional product, we focused on the effect of CLPABP on the stability of mRNA involving an AU-rich element (ARE) in its 3'UTR dependence on the RNA stabilizer, human antigen R (HuR), which is one of the CLPABP-binding proteins. Increase in stability of ARE-containing mRNAs of leptin by HuR was antagonized by the expression of CLPABP in cultured cells. Depletion of CLPABP disturbed the normal subcellular localization of HuR to stress granules, and overexpression of CLPABP induced instability of leptin mRNA by inhibiting HuR function. Consequently, leptin levels in old male mice might be regulated by CLPABP expression, which might lead to body weight control.
  • Seiya Arita, Yuta Kinoshita, Kaori Ushida, Atsushi Enomoto, Kyoko Inagaki-Ohara
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 610 16-24, Nov, 2016  Peer-reviewed
  • Kyoko Inagaki-Ohara, Shiki Okamoto, Kazuyo Takagi, Kumiko Saito, Seiya Arita, Lijun Tang, Tetsuji Hori, Hiroaki Kataoka, Satoshi Matsumoto, Yasuhiko Minokoshi
    NUTRITION & METABOLISM, 13 7-7, Feb, 2016  Peer-reviewed
  • Tomoyuki Oshio, Rei Kawashima, Yuki I. Kawamura, Teruki Hagiwara, Noriko Mizutani, Toshihiko Okada, Takeshi Otsubo, Kyoko Inagaki-Ohara, Akihiro Matsukawa, Tatsuya Haga, Shigeru Kakuta, Yoichiro Iwakura, Seijiro Hosokawa, Taeko Dohi
    PLOS ONE, 9(4) e94445, Apr, 2014  Peer-reviewed
  • INAGAKI-OHARA Kyoko
    J. Mol. Biochem., 3 85-96, 2014  Peer-reviewed
  • K. Inagaki-Ohara, H. Mayuzumi, S. Kato, Y. Minokoshi, T. Otsubo, Y. I. Kawamura, T. Dohi, G. Matsuzaki, A. Yoshimura
    ONCOGENE, 33(1) 74-84, Jan, 2014  Peer-reviewed
  • A. Son, T. Oshio, Y. I. Kawamura, T. Hagiwara, M. Yamazaki, K. Inagaki-Ohara, T. Okada, P. Wu, M. Iseki, S. Takaki, L. C. Burkly, T. Dohi
    MUCOSAL IMMUNOLOGY, 6(6) 1131-1142, Nov, 2013  Peer-reviewed
  • INAGAKI-OHARA Kyoko
    JAKSTAT, 2(3) e24053, Jul, 2013  Peer-reviewed
    Signal transduction pathways elicited by cytokines and hormones have been shown to regulate distinct stages of development. Suppressor of cytokine signaling (SOCS) proteins are negative feedback regulators of cytokine signaling mediated by the JAK-STAT signaling pathway. In particular, SOCS1 and SOCS3 are potent inhibitors of JAKs and can play pivotal roles in inflammation, as well as in the development and progression of cancers. Abnormal expression of SOCS1 and SOCS3 in cancer cells has been reported in human carcinoma associated with dysregulation of signals from cytokine receptors, Toll-like receptors (TLRs), and hormone receptors, resulting in malignancies. In this review, we focus on the role of SOCS1 and SOCS3 in cancer development. In addition, the potential of SOCS as a therapeutic target and diagnostic aid will be discussed.
  • Shinya Ashizuka, Haruhiko Inatsu, Kyoko Inagaki-Ohara, Toshihiro Kita, Kazuo Kitamura
    CURRENT PROTEIN & PEPTIDE SCIENCE, 14(4) 246-255, Jun, 2013  Peer-reviewed
  • Toshihiko Okada, Shinji Fukuda, Koji Hase, Shin Nishiumi, Yoshihiro Izumi, Masaru Yoshida, Teruki Hagiwara, Rei Kawashima, Motomi Yamazaki, Tomoyuki Oshio, Takeshi Otsubo, Kyoko Inagaki-Ohara, Kazuki Kakimoto, Kazuhide Higuchi, Yuki I. Kawamura, Hiroshi Ohno, Taeko Dohi
    NATURE COMMUNICATIONS, 4 1654-1654, Apr, 2013  Peer-reviewed
  • Kiyotetsu Oshiro, Hideyasu Kohama, Masayuki Umemura, Catherine Uyttenhove, Kyoko Inagaki-Ohara, Takeshi Arakawa, Mamoru Harada, Susumu Nakae, Yoichiro Iwakura, Tadashi Nishimaki, Goro Matsuzaki
    IMMUNOBIOLOGY, 217(1) 54-60, Jan, 2012  Peer-reviewed
  • Rei Kawashima, Yuki I. Kawamura, Tomoyuki Oshio, Aoi Son, Motomi Yamazaki, Teruki Hagiwara, Toshihiko Okada, Kyoko Inagaki-Ohara, Ping Wu, Suzanne Szak, Yutaka J. Kawamura, Fumio Konishi, Oki Miyake, Hideaki Yano, Yukio Saito, Linda C. Burkly, Taeko Dohi
    GASTROENTEROLOGY, 141(6) 2119-U266, Dec, 2011  Peer-reviewed
  • Kyoko Inagaki-Ohara, Yukiko Sakamoto, Taeko Dohi, Adrian L. Smith
    IMMUNOLOGY, 134(4) 448-458, Dec, 2011  Peer-reviewed
  • Kumiko Saito, Suni Lee, Tetsuya Shiuchi, Chitoku Toda, Masahiro Kamijo, Kyoko Inagaki-Ohara, Shiki Okamoto, Yasuhiko Minokoshi
    ANALYTICAL BIOCHEMISTRY, 412(1) 9-17, May, 2011  Peer-reviewed
  • Kumiko Saito, Suni Lee, Tetsuya Shiuchi, Chitoku Toda, Masahiro Kamijo, Kyoko Inagaki-Ohara, Shiki Okamoto, Yasuhiko Minokoshi
    Analytical Biochemistry: Methods in the Biological Sciences, Vol.412(No.1) 9-17, Jan 22, 2011  Peer-reviewed
    An enzymatic assay adapted to photometric analysis with 96-well microplates was evaluated for the measurement of 2-deoxyglucose (2DG) uptake in insulin-responsive tissues and differentiated 3T3-L1 adipocytes. For in vivo measurements, a small amount of nonradiolabeled 2DG was injected into mice without affecting glucose metabolism. For photometric quantification of the small amount of 2-deoxyglucose 6-phosphate (2DG6P) that accumulates in cells, we introduced glucose-6-phosphate dehydrogenase, glutathione reductase, and 5,5'-dithiobis(2-nitrobenzoic acid) to the recycling amplification reaction of NADPH. We optimized the enzyme reaction for complete oxidation of endogenous glucose 6-phosphate (G6P) and glucose in mouse tissues in vivo and serum as well as in 3T3-L1 adipocytes in vitro. All reactions are performed in one 96-well microplate by consecutive addition of reagents, and the assay is able to quantify 2DG and 2DG6P in the range of 5-80 pmol. The results obtained with the assay for 2DG uptake in vitro and in vivo in the absence or presence of insulin stimulation was similar to those obtained with the standard radioisotopic method. Thus, the enzymatic assay should prove to be useful for measurement of 2DG uptake in insulin-responsive tissues in vivo as well as in cultured cells.
  • Hirokazu Mayuzumi, Kyoko Inagaki-Ohara, Catherine Uyttenhove, Yuko Okamoto, Goro Matsuzaki
    IMMUNOLOGY, 131(3) 377-385, Nov, 2010  Peer-reviewed
  • Shinya Ashizuka, Kyoko Inagaki-Ohara, Kenji Kuwasako, Johji Kato, Haruhiko Inatsu, Kazuo Kitamura
    MICROBIOLOGY AND IMMUNOLOGY, 53(10) 573-581, Oct, 2009  Peer-reviewed
  • Ayman Samir Farid, Fumiko Jimi, Kyoko Nagaki-Ohara, Yoichiro Horii
    SHOCK, 29(6) 709-716, Jun, 2008  Peer-reviewed
  • Kyoko Inagaki-Ohara, Fitriya Nurannisa Dewi, Hajime Hisaeda, Adrian L. Smith, Fumiko Jimi, Maki Miyahira, Ayman Samir Farid Abdel-Aleem, Yoichiro Horii, Yukifumi Nawa
    INFECTION AND IMMUNITY, 74(9) 5292-5301, Sep, 2006  Peer-reviewed
  • K Inagaki-Ohara, A Sasaki, G Matsuzaki, T Ikeda, M Hotokezaka, K Chijiiwa, M Kubo, H Yoshida, Y Nawa, A Yoshimura
    GUT, 55(2) 212-219, Feb, 2006  Peer-reviewed
  • K Inagaki-Ohara, A Sawaguchi, T Suganuma, G Matsuzaki, Y Nawa
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 331(4) 977-983, Jun, 2005  Peer-reviewed
  • K Inagaki-Ohara, G Matsuzaki, A Sasaki, Y Nawa, A Yoshimura
    IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY, 173(2) 485-489, 2004  Peer-reviewed
  • Y Seki, H Inoue, N Nagata, K Hayashi, S Fukuyama, K Matsumoto, O Komine, S Hamano, K Himeno, K Inagaki-Ohara, N Cacalano, A O'Garra, T Oshida, H Saito, JA Johnston, A Yoshimura, M Kubo
    NATURE MEDICINE, 9(8) 1047-1054, Aug, 2003  Peer-reviewed
  • K Inagaki-Ohara, T Hanada, A Yoshimura
    CURRENT OPINION IN PHARMACOLOGY, 3(4) 435-442, Aug, 2003  Peer-reviewed
  • K Inagaki-Ohara, N Takamura, S Yada, Z Alnadjim, ED Liu, XH Yu, H Yoshida, TS Lin
    DIGESTIVE DISEASES AND SCIENCES, 47(12) 2823-2830, Dec, 2002  Peer-reviewed
  • Kinjyo, I, T Hanada, K Inagaki-Ohara, H Mori, D Aki, M Ohishi, H Yoshida, M Kubo, A Yoshimura
    IMMUNITY, 17(5) 583-591, Nov, 2002  Peer-reviewed
  • K Inagaki-Ohara, T Iwasaki, D Watanabe, T Kurata, Y Nishiyama
    VACCINE, 20(1-2) 98-104, Oct, 2001  Peer-reviewed
  • S Murosaki, K InagakiOhara, H Kusaka, H Ikeda, Y Yoshikai
    MICROBIOLOGY AND IMMUNOLOGY, 41(2) 139-148, 1997  Peer-reviewed

Misc.

 30

Books and Other Publications

 2

Major Professional Memberships

 4

Research Projects

 12